Osteoarthritis (OA) affects 500 million people in Europe. Available therapies are associated with moderate efficacy and long-term side effects.
The vision of the international team of the EU research project SINPAIN is to improve the quality of life for those affected by OA and reduce the substantial costs linked with the disease by developing a new generation of OA therapeutics. To achieve this, SINPAIN is developing an innovative nanotherapeutics pipeline based on siRNA for treating different stages of knee OA.
Overall, the envisioned therapeutics could alleviate the pain of knee osteoarthritis patients worldwide.